Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces the semaglutide ...

Novo Nordisk stock (DK:NOVO.B) (NVO) rose 2% in Copenhagen trade. But the stock is still down about 28% this year and less than half the value of its peak last June. The company said its first ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...

Booming sales of Wegovy helped to make Novo the most valuable listed company in Europe ... Jorgensen said on a call with journalists. Novo Nordisk said first-quarter sales of Wegovy were 17. ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Novo Nordisk imply an improvement in the company's underlying business. Investors should show their ...